Validation of a novel 3D culture platform for TNBC treatment selection
验证用于 TNBC 治疗选择的新型 3D 培养平台
基本信息
- 批准号:10540094
- 负责人:
- 金额:$ 64.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-20 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAdriamycin PFSArchitectureBiological AssayBiotechnologyBreast Cancer PatientBreast Cancer TreatmentBusinessesCancer CenterCancer DiagnosticsCancer PatientCarboplatinCellsCessation of lifeCharacteristicsChemicalsClinicalClinical DataClinical ResearchClinical TrialsCyclophosphamideDataDiagnostic testsDoxorubicinEngineeringEvaluationGenomicsGoalsImmuno-ChemotherapyImmunotherapyIndividualIndustrializationLegal patentMalignant NeoplasmsMeasuresMechanicsMethodist ChurchMethodsModelingMolecular ProfilingMutationNeoadjuvant TherapyOncologyOrganoidsOutcomePaclitaxelPatient CarePatient Care TeamPatient-derived xenograft models of breast cancerPatientsPharmaceutical PreparationsPhysiciansProspective StudiesReagentReportingResearchResearch InstituteResolutionRetrospective StudiesScientistSelection for TreatmentsSerumSliceSolidSolid NeoplasmSystemT-Cell ActivationTestingTimeTissuesTranslatingTumor BiologyTumor TissueValidationanti-PD-L1anti-PD-L1 therapyanticancer researchbasecancer carecancer diagnosischemotherapyclinical careclinical practiceclinical translationclinically actionablecostdesigndiagnostic assaydrug sensitivityevidence basegenomic profilesimprovedin vivoindividual patientmalignant breast neoplasmmetastatic colorectalmouse modelnovelpatient derived xenograft modelpatient responsepembrolizumabpersonalized carepersonalized medicineprecision drugsprecision medicineproduct developmentprospectiveresistance mechanismresponders and non-respondersresponsestandard of caretargeted treatmenttaxanethree dimensional cell culturetissue culturetreatment responsetreatment strategytriple-negative invasive breast carcinomatumortumor immunologytumor microenvironment
项目摘要
PROJECT SUMMARY
The goal of this academic [Houston Methodist Research Institute (HMRI) and MD Anderson Cancer
Center (MDACC)] and industrial (EMPIRI) collaborative project is to validate a novel, functional cancer
diagnostic assay for clinical translation to improve and personalize the care of triple-negative breast cancer
(TNBC) patients. The study will validate a novel 3D tumor tissue culture method (E-slices) invented by MPI
Kyuson Yun (HMRI) and licensed to EMPIRI, Inc., a biotech startup co-founded by Dr. Yun and Dave Gallup
(MPI). Together with Dr. Naoto Ueno (MPI, MDACC), a renowned physician-scientist specializing in TNBC
research and patient care, the team will validate the predictive accuracy of E-slices for individual TNBC patient
responses to recently approved chemoimmunotherapy for early TNBC patient care.
The need for personalized medicine in oncology is widely accepted but translating this important concept
into clinical practice has been challenging. Currently, the dominant platform for precision medicine utilizes
genomics/sequencing-based assays to measure the expression and/or mutational profiles and then infer
responses to targeted therapies; however, this approach benefits <10% of patients with profiled tumors.
Recognizing the inherent limitations of these inference-based methods, functional assays (e.g., organoids, PDX
models) have been developed, but these approaches have numerous limitations including high cost and time
required to establish the models, low “take rates”, and destruction of the native tumor microenvironment (TME).
To overcome these challenges, EMPIRI developed a novel 3D ex vivo tumor culture method (E-slices)
that enables rapid, personalized drug sensitivity testing in intact patient tumor tissues. E-slices retain the
native TME and tissue architecture and are cultured in serum-free defined media, overcoming the limitations of
other approaches. In addition, E-slices can be generated from any solid tumor and used for testing responses to
chemotherapy, targeted therapy, and immunotherapy. Importantly, E-slice accuracy has been validated in a
clinical setting for metastatic colorectal cancer to accurately predict individual patient treatment responses and
detect inter-patient differences to the same treatments in 4-12 days, paving the way for near evidence-based
personalized treatment selections. The team will: (i) determine whether E-slices predict patient responses to
SOC NAC: doxorubicin (Adriamycin) plus cyclophosphamide) in a retrospective study, (ii) measure
chemoimmunotherapy (Pembrolizumab plus paclitaxel + carboplatin) responses in humanized PDX slices from
known responders and non-responders; and (ii) evaluate the clinical utility of E-slices in predicting TNBC patient
responses to newly approved standard of care chemoimmunotherapy in a prospective study. Successful
completion of this project will provide the necessary data to apply E-slices as the first functional cancer diagnostic
test specifically designed to inform TNBC patient care.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Gallup其他文献
David Gallup的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Gallup', 18)}}的其他基金
Validation of a novel 3D culture platform for TNBC treatment selection
验证用于 TNBC 治疗选择的新型 3D 培养平台
- 批准号:
10707311 - 财政年份:2022
- 资助金额:
$ 64.42万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 64.42万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 64.42万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 64.42万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 64.42万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 64.42万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 64.42万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 64.42万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 64.42万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 64.42万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 64.42万 - 项目类别:
Research Grant














{{item.name}}会员




